Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
January 28, 2022 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference
January 18, 2022 08:30 ET
|
LAVA Therapeutics N.V.
The collective data indicate that LAVA’s approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and...
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
December 20, 2021 10:06 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph...
LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
December 20, 2021 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
Florida Cancer Specialists & Research Institute Celebrates Opening of New State-of-the-Art Cancer Center in Bradenton
November 18, 2021 17:17 ET
|
Florida Cancer Specialists & Research Institute
Bradenton, Fla, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) held a ribbon-cutting ceremony Wednesday, to mark the opening of its new state-of-the-art...
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 15, 2021 07:00 ET
|
LAVA Therapeutics N.V.
LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on...
HCW Biologics Reports Third Quarter Financial Results and Recent Business Highlights
November 12, 2021 07:00 ET
|
HCW Biologics, Inc
MIRAMAR, Fla., Nov. 12, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), an innovative biopharmaceutical company focused on discovering and developing...
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
November 11, 2021 10:08 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that...
LAVA Therapeutics Expands Management Team with Three Key Appointments
November 09, 2021 06:30 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
November 04, 2021 07:00 ET
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...